These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36171121)

  • 21. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephrotic syndrome relapse in a boy with COVID-19.
    Enya T; Morimoto Y; Oshima R; Miyazaki K; Miyazawa T; Okada M; Sugimoto K
    CEN Case Rep; 2021 Aug; 10(3):431-434. PubMed ID: 33616881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases.
    Martínez-Chinchilla C; Vazquez-Montero L; Palazón-Carrión N; Fernández-Román IM; López-Barba J; de la Cruz-Merino L; Rodríguez-Baño J; Palacios-Baena ZR
    Front Immunol; 2022; 13():860891. PubMed ID: 35493500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab.
    Takakuwa T; Nakagama Y; Yasugi M; Maeda T; Matsuo K; Kiritoshi A; Deguchi R; Hagawa N; Shibata W; Oshima K; Yamamoto K; Uchida K; Noda T; Yamada K; Nishimura T; Yamamoto H; Kido Y; Hino M; Kakeya H; Mizobata Y
    Intern Med; 2021; 60(23):3827-3831. PubMed ID: 34853259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membranous nephropathy after a recent SARS-CoV-2 infection.
    Mateus C; Theias Manso R; Martins AR; Branco PQ
    BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36707097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS.
    Adachi E; Saito M; Koga M; Tsutsumi T; Yotsuyanagi H
    Intern Med; 2022 Nov; 61(22):3459-3462. PubMed ID: 36070950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.
    Koehler J; Ritzer B; Weidlich S; Gebhardt F; Kirchhoff C; Gempt J; Querbach C; Hoffmann D; Haller B; Schmid RM; Schneider J; Spinner CD; Iakoubov R
    Infection; 2021 Dec; 49(6):1313-1318. PubMed ID: 34244967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.
    Benz K; Dötsch J; Rascher W; Stachel D
    Pediatr Nephrol; 2004 Jul; 19(7):794-7. PubMed ID: 15071769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Casirivimab-imdevimab monoclonal antibody treatment for an immunocompromised patient with persistent SARS-CoV-2 infection: a case report.
    Sam KS; Khosla P; Taneja V; Dessai R
    Commun Med (Lond); 2024 Jun; 4(1):103. PubMed ID: 38824216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19.
    Parums DV
    Med Sci Monit; 2021 Aug; 27():e934393. PubMed ID: 34393218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome.
    Kurosu N; Sugiura H; Iwasaki C; Asamiya Y; Kojima C; Moriyama T; Itabashi M; Tsukada M; Takei T; Ogawa T; Yoshida T; Uchida K; Tsuchiya K; Nitta K
    Intern Med; 2009; 48(21):1901-4. PubMed ID: 19881243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response.
    Kim PS; Dimcheff DE; Siler A; Schildhouse RJ; Chensue SW
    Clin Immunol; 2022 Mar; 236():108959. PubMed ID: 35218964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall.
    Tuccori M; Convertino I; Ferraro S; Cappello E; Valdiserra G; de Luca G; Franchini M; Focosi D
    Expert Opin Drug Discov; 2022 Jun; 17(6):531-546. PubMed ID: 35361043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent SARS-CoV-2 infection in patients with B-cell deficiency: a case series of successful antiviral treatment of four patients.
    Faxén L; Edvinsson M
    Ups J Med Sci; 2023; 128():. PubMed ID: 37849689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection.
    Sloan B; Duhaime E; Sandkovsky U; Berhe M
    Proc (Bayl Univ Med Cent); 2022; 35(3):339-341. PubMed ID: 35518791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes.
    Hayek S; Ben-Shlomo Y; Dagan N; Reis BY; Barda N; Kepten E; Roitman A; Shapira S; Yaron S; Balicer RD; Netzer D; Peretz A
    Nat Commun; 2022 Aug; 13(1):4480. PubMed ID: 35918340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case Report of COVID-19 Infection After Kidney Transplant Treated With Casirivimab-Imdevimab and Mycophenolate Mofetil Changed to Everolimus.
    Kijima Y; Shimizu T; Kato S; Kano K; Horiuchi T; Nozaki T; Omoto K; Inui M; Toma H; Iida S; Takagi T
    Transplant Proc; 2022; 54(6):1561-1563. PubMed ID: 35065832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective Case-Control Study of REGEN-COV (Casirivimab and Imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan® Database.
    Takemoto K
    Oncology; 2024; 102(3):195-205. PubMed ID: 37666220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
    DaSilva I; Huerta A; Quintana L; Redondo B; Iglesias E; Draibe J; Praga M; Ballarín J; Díaz-Encarnación M;
    BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.